Clinical trials: PPA
Alzheimer Disease
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
This first-time-in-man study is mainly designed to assess the safety and tolerability of AADvac1 in the treatment of Alzheimer's disease.
- Trial name
- NCT01850238
- Testing
- AADvac1
- Where
- 3 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Axon Neuroscience SE
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT07498426
- Testing
- NIO752
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Cognition, Affect (Mental Function)
ETASCAI Pilot Project
This pilot study aims to investigate the chronic effects of ETAS® on cognitive, affective and inflammatory outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
- Conditions
- Cognition, Affect (Mental Function), Inflammation
- Trial name
- NCT06790849
- Testing
- Active 1 ETAS®, Active 2 ETAS®
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Reading
Niemann-Pick Disease, Type C1
Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1
Background: For people who have Niemann-Pick disease, type C1 (NPC1), cholesterol and other fats have trouble moving out of liver and other tissue cells. This makes the cells sick.
- Trial name
- NCT03887533
- Testing
- VTS-270
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Dementia (Diagnosis), Alzheimer Dementia (AD)
Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)
The goal of this observational study is to learn if an artificial intelligence (AI)-based speech analysis tool can identify which patients with memory problems need specialist evaluation at a memory clinic.
- Conditions
- Dementia (Diagnosis), Alzheimer Dementia (AD), Vascular Dementia (VaD), Lewy Body Dementia (LBD)
- Trial name
- DetectAI (NCT07200739)
- Testing
- Mini-mental State Examination, Addenbrooke's Cognitive Examination, Speech Task - Picture Description
- Where
- Denmark
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Zealand University Hospital
Pulmonary Disease, Chronic Obstructive
A Prescription-Event Monitoring (PEM) Study of Tiotropium
This prescription-event monitoring study was based upon 'event' monitoring and so capable of identifying signals of events that might be associated with the use of tiotropium, which none of the participating general practitioners…
- Trial name
- NCT02196194
- Testing
- Tiotropium
- Volunteers
- 13,891 people
- Sponsor
- Boehringer Ingelheim
Primary Progressive Aphasia, MCI
tDCS Intervention in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g.
- Conditions
- Primary Progressive Aphasia, MCI, FTD
- Trial name
- NCT02606422
- Testing
- Active HD-tDCS plus Speech-Language Therapy
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Common Cold, Cough
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on…
- Trial name
- NCT06716645
- Testing
- Robitussin Maximum Strength Cough and Chest Congestion DM, Robitussin Maximum Strength Nighttime Cough DM
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- HALEON
Primary Progressive Aphasia
Transcranial Magnetic Stimulation in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a clinical syndrome characterized by the neurodegeneration of language brain systems. Three main clinical variants are currently recorgnized (nonfluent, semantic, and logopenic PPA).
- Trial name
- NCT03580954
- Testing
- Transcranial Magnetic Stimulation
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital San Carlos, Madrid
Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions
ECOCAPTURE@HOME is a study which is currently being developed with the objective to capture the behavioral signature of apathy in everyday life context through remote monitoring of participants' behavior for about one month.
- Trial name
- @HOME (NCT04865172)
- Testing
- Remote collection of passive and active data for 28 consecutive days
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Frontotemporal Lobar Degeneration
Treatment Study of Frontotemporal Dementia
Objectives. The proposed clinical study has two goals: First, to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD and second, to further…
- Trial name
- NCT00088751
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Frontotemporal Dementia
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients…
- Trial name
- PROCLAIM (NCT04408625)
- Testing
- LY3884963, Methylprednisolone, Optional Sirolimus
- Where
- 12 sites in United States, Australia and 4 more
- Volunteers
- 35 people
- Sponsor
- Prevail Therapeutics
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Therapy in Amyotrophic Lateral Sclerosis (TAME)
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their…
- Trial name
- TAME (NCT02118727)
- Testing
- Memantine
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Kansas Medical Center